Home/BeyondSpring/Dr. Douglas Blayney

DD

Dr. Douglas Blayney

Scientific Advisory Board Member, Professor at Stanford University

Therapeutic Areas

Oncology Supportive Cancer Care

BeyondSpring Pipeline

Drug	Indication	Phase
Plinabulin + G-CSF	Prevention of Chemotherapy-Induced Neutropenia (CIN)	Phase 3
Plinabulin	Non-Small Cell Lung Cancer (NSCLC)	Phase 2/3
BPI-002	Undisclosed Oncology Target	Preclinical

Leadership Team at BeyondSpring

Co-Founder, Chief Executive Officer, and Chairwoman of the Board

Dr. Ramon Mohanlal

Former Chief Medical Officer and EVP of Research & Development

Founder and Director

View full BeyondSpring profile